CA2799162A1 - Traitement du tcl et de la maladie d'alzheimer - Google Patents

Traitement du tcl et de la maladie d'alzheimer Download PDF

Info

Publication number
CA2799162A1
CA2799162A1 CA2799162A CA2799162A CA2799162A1 CA 2799162 A1 CA2799162 A1 CA 2799162A1 CA 2799162 A CA2799162 A CA 2799162A CA 2799162 A CA2799162 A CA 2799162A CA 2799162 A1 CA2799162 A1 CA 2799162A1
Authority
CA
Canada
Prior art keywords
nifedipine
pharmaceutical composition
nitroso
lactam
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2799162A
Other languages
English (en)
Inventor
Mark Lovell
Bert Lynn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Kentucky Research Foundation
Original Assignee
University of Kentucky Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2010/034721 external-priority patent/WO2010132671A1/fr
Application filed by University of Kentucky Research Foundation filed Critical University of Kentucky Research Foundation
Publication of CA2799162A1 publication Critical patent/CA2799162A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2799162A 2010-05-13 2010-11-18 Traitement du tcl et de la maladie d'alzheimer Abandoned CA2799162A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
USPCT/US2010/034721 2010-05-13
PCT/US2010/034721 WO2010132671A1 (fr) 2009-05-15 2010-05-13 Traitement du trouble cognitif léger et de la maladie d'alzheimer
PCT/US2010/057287 WO2011142778A1 (fr) 2010-05-13 2010-11-18 Traitement du tcl et de la maladie d'alzheimer

Publications (1)

Publication Number Publication Date
CA2799162A1 true CA2799162A1 (fr) 2011-11-17

Family

ID=44923820

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2799162A Abandoned CA2799162A1 (fr) 2010-05-13 2010-11-18 Traitement du tcl et de la maladie d'alzheimer

Country Status (6)

Country Link
EP (1) EP2568811A4 (fr)
JP (1) JP2013526518A (fr)
CN (1) CN102984938A (fr)
AU (1) AU2010353287A1 (fr)
CA (1) CA2799162A1 (fr)
WO (1) WO2011142778A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014182631A1 (fr) * 2013-05-06 2014-11-13 Baxter International Inc. Traitement de sous-populations atteintes de la maladie d'alzheimer avec de l'immunoglobuline g rassemblée
CA2937529A1 (fr) * 2014-01-29 2015-08-06 Bristol-Myers Squibb Company Inhibiteurs d'aryl-lactame kinase
CN106177046A (zh) * 2016-08-29 2016-12-07 杨添福 一种基于普立宁钾开发的神经认知障碍治疗药物及其制备方法
CN106645505A (zh) * 2016-11-18 2017-05-10 中国医科大学 可实现glt‑1蛋白鉴定及绝对定量的试剂盒及测定方法
CN107022019B (zh) * 2016-11-24 2020-10-30 桂林医学院 一种用于脑内降铁除自由基的多肽、制备方法与应用
CN106636388A (zh) * 2016-12-15 2017-05-10 湖南中能荆卫生物科技有限公司 用于亨廷顿病诊断的基因及其应用以及由其编码的蛋白和蛋白的应用
CN108191966B (zh) * 2018-01-11 2020-10-27 桂林医学院 一种含导肽可穿越血脑屏障螯合脑内铁降自由基的多肽
CN113853382A (zh) * 2019-01-07 2021-12-28 森纳生物科学公司 新型肽及其用途
JP7321017B2 (ja) * 2019-07-17 2023-08-04 東海物産株式会社 機能性食品

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8002A (en) * 1851-03-25 Upright pianoforte
DE2126533A1 (de) * 1971-05-28 1972-12-14 Merck Patent Gmbh, 6100 Darmstadt Verfahren zur Herstellung pharma zeutischer Zubereitungen
AU744179B2 (en) * 1998-04-08 2002-02-14 Oregon Health Sciences University Enhancement of cellular gallium uptake
US6489319B2 (en) * 1999-08-16 2002-12-03 Revaax Pharmaceuticals, Llc Neurotherapeutic use of carboxypeptidase inhibitors
WO2002041893A1 (fr) * 2000-11-21 2002-05-30 Howard Zik Utilisation de bloqueurs du canal calcium à la 1,4-dihydropyridine pour traiter des atteintes neurologiques imputables au virus de l'herpès
US20080026081A1 (en) * 2003-11-21 2008-01-31 Axel Unterbeck Methods of Treatment Using (+)-Isopropyl 2-Ethoxyethyl-4-(2-Chloro-3-Cyano-Phenyl)-1,4-Dihydro-2,6-Dimethyl-Pyridine-3,5-Dicarboxylate
EP1874311B1 (fr) * 2005-04-15 2011-10-05 Research & Innovation S.p.A. Methode pour prevenir, retarder ou inverser la progression de pathologies associees a un depot amyloide anormal
EP1955698B1 (fr) * 2005-12-02 2013-10-30 Mochida Pharmaceutical Co., Ltd. Agent preventif/therapeutique contre la demence d'alzheimer
EP2007385A4 (fr) * 2006-03-23 2010-08-18 Sinai School Medicine Composition cardiovasculaire et utilisation de ladite composition pour le traitement de la maladie d'alzheimer
CA2648243C (fr) * 2006-04-11 2015-12-22 Shaker A. Mousa Nanoparticule et formes polymeres d'analogues et d'antagonistes de l'hormone thyroidienne et leurs formulations
US20080293712A1 (en) * 2007-03-05 2008-11-27 Wyeth Benzo[C][2,7]Naphtyridine Derivatives, Methods of Making Thereof and Methods of Use Thereof
WO2010034110A1 (fr) * 2008-09-25 2010-04-01 Merck Frosst Canada Ltd. Dérivés de bêta-carboline sulfonylurée en tant qu’antagonistes du récepteur d’ep4
TW201103907A (en) * 2009-03-20 2011-02-01 Lundbeck & Co As H Amide derivatives as neuropeptide Y5 receptor ligands

Also Published As

Publication number Publication date
JP2013526518A (ja) 2013-06-24
WO2011142778A1 (fr) 2011-11-17
EP2568811A1 (fr) 2013-03-20
EP2568811A4 (fr) 2014-03-12
CN102984938A (zh) 2013-03-20
AU2010353287A1 (en) 2012-11-29

Similar Documents

Publication Publication Date Title
CA2799162A1 (fr) Traitement du tcl et de la maladie d'alzheimer
US20100292281A1 (en) Treatment of mci and alzheimer's disease
Pohanka Alzheimer s disease and oxidative stress: a review
ES2573733T3 (es) Tratamiento farmacológico del deterioro cognitivo
US9968574B2 (en) Treatment of MCI and Alzheimer's disease
KR20110071050A (ko) 알츠하이머 질환 및 관련 장애의 치료를 위한 조니사미드 및 아캄프로세이트의 조합 조성물
WO2008006070A2 (fr) Composés et combinaisons de ceux-ci pour inhiber la production de bêta-amyloïde et procédés d'utilisation de ces composés et combinaisons
KR20120055692A (ko) 화학요법에 의해 유도되는 통증의 예방 또는 치료를 위한 시그마 리간드
JP2016521755A (ja) 代謝障害を治療するための組成物および方法
WO2011050095A2 (fr) Prévention et traitement des dysfonctions cognitives postopératoires (pocd)
WO2017015660A1 (fr) Prévention et traitement du vieillissement et de maladies neurodégénératives
Fernandez‐Perez et al. Synaptic dysregulation and hyperexcitability induced by intracellular amyloid beta oligomers
EP1707202A1 (fr) Composes organiques
WO2012154285A1 (fr) Quantités efficaces de (3ar)-1,3a,8-triméthyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phénylcarbamate et leurs procédés
US20100247688A1 (en) Pirenzepine and derivatives thereof as anti-amyloid agents
WO2018112626A1 (fr) Inhibition de la caspase-1 et ses utilisations dans la prévention et le traitement d'états neurologiques
KR101173677B1 (ko) Ｅｐｐｓ를 유효성분으로 함유하는 베타아밀로이드 집적 관련 질환의 예방 또는 치료용 약학적 조성물
ES2374716T3 (es) Método para prevenir, retrasar o revertir la deposición anormal de amiloide.
DK2462131T3 (en) Preparations and Methods for Treating Beta-Amyloid-Related Diseases
Sose et al. An Update on Autophagy as a Target in the Treatment of Alzheimer’s Disease
ES2449594T3 (es) Método para reducir deposición amiloide, neurotoxicidad amiloide y microgliosis con enantiomero (-)-nilvadipina
Ranade et al. TARGET EVOLUTION AND THERAPY ADVANCEMENTS FOR ALZHEIMER’S DISEASE: A REVIEW
EA041317B1 (ru) Синергетические композиции, содержащие (r)-димирацетам (1) и (s)-димирацетам (2) в нерацемическом соотношении
WO2024064897A1 (fr) Procédés de réduction de la neurodégénérescence associée à des maladies neurodégénératives
KR20130030011A (ko) 뇌손상에 의한 전두엽 기능장애 모델 동물 및 전두엽 기능장애의 개선용 조성물

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20161118